Riskpilot← Back to searchSign inGet full accessPHARMACOSMOS HOLDING A/S
A/SActiveCVR 69720919Rørvangsvej 30Activities of holding companies · NACE 6421Est. 19651 employees
Revenue 2025
DKK 3,4B
+8227% vs 2024
EBITDA margin
77.1%
+23034% vs 2024
Equity ratio
39.9%
Financial strength
Net profit 2025
DKK 1,7B
+104% vs 2024
| Revenue | DKK 3,4B | +8227% |
| EBITDA | DKK 2,6B | +23034% |
| Net profit | DKK 1,7B | +104% |
| Total assets | DKK 5,7B | +206% |
| Equity | DKK 2,3B | +24% |
| Employees | 1 | — |
Legal name
PHARMACOSMOS HOLDING A/S
CVR number
69720919
Legal form
Aktieselskab
NACE code
6421 · Activities of holding companies
Founded
12. oktober 1965
Share capital
DKK 6.000.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, eller af et medlem af direktionen og et medlem af bestyrelsen i forening, eller af Tobias Sidelmann Christensen alene.
Company purpose
Selskabets formål er
at drive virksomhed med udvikling af farmaceutiske, kemiske og tekniske produkter og processer og erhverve, eje, disponere og administrere over rettigheder i forbindelse hermed,
at eje kapitalandele i selskaber som driver virksomhed med udvikling, produktion og handel med farmaceutiske, kemiske og tekniske produkter, anlæg og lignende,
at foretage investeringsvirksomhed og finansiering, herunder anbringelse af kapital i fast ejendom og i virksomheder i ind- og udland,
samt efter bestyrelsens skøn at drive anden i forbindelse dermed stående virksomhed.
Address
Rørvangsvej 30
Phone
+4559485959
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2.684 | 23.552 | 30.638 | 40.373 | 3.362.000 |
| Staff expenses | -0 | -0 | -16.067 | -0 | -0 |
| EBITDA | -4.734 | 297 | 8.093 | 11.200 | 2.591.000 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -264.000 |
| EBIT | -4.734 | 297 | 8.093 | 11.200 | 2.327.000 |
| Net financials | -122.847 | 184.388 | 122.603 | 801.884 | 1.434.000 |
| Profit before tax | -127.581 | 184.685 | 130.696 | 813.084 | 2.129.000 |
| Tax | -3.568 | 249 | 2.052 | 4.401 | 477.000 |
| Net profit | -124.013 | 184.436 | 128.644 | 808.683 | 1.652.000 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 792.364 | 983.871 | 1.052.477 | 1.862.557 | 5.696.000 |
| Equity | 790.862 | 969.925 | 1.031.422 | 1.831.595 | 2.273.000 |
| Long-term debt | 0 | 0 | 0 | 0 | 2.123.000 |
| Short-term debt | 1.502 | 13.946 | 21.055 | 30.962 | 1.300.000 |
| Total debt | 1.502 | 13.946 | 21.055 | 30.962 | 3.423.000 |
EBITDA margin
77.1%
This company
15.8%
Market median
+388% vs market
20212025
Equity ratio
39.9%
This company
38.2%
Market median
+4% vs market
20212025
Return on equity
72.7%
This company
18.4%
Market median
+295% vs market
20212025
Net profit margin
49.1%
This company
8.1%
Market median
+506% vs market
20212025
Asset turnover
0.59×
This company
1.12×
Market median
-47% vs market
20212025
Debt / equity
1.51×
This company
0.62×
Market median
-144% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TS Chief Executive Officer | Chief Executive Officer | 2022 |
HP Management | Management | 2023 |
| Former (2) | ||
| Audit | 1965 – 1988 | |
RG Management | Management | 2010 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Board of Directors | 2020 | |
| Former (8) | ||
| Board of Directors | 2002 – 2020 | |
| Chairman | 2019 – 2020 | |
| Chairman | 1965 – 1996 | |
| Board of Directors | 1965 – 2002 | |
| Chairman | 1965 – 2002 | |
| Board of Directors | 1965 – 1994 | |
| Board of Directors | 1965 – 1990 | |
| Chairman | 2002 – 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 | |
| Company | 33.33–49.99% | 5–9.99% | 2013 | |
| Company | 50–66.65% | 90–99.99% | 2008 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ANTOAX A/S
PHARMACOSMOS HOLDING A/S Board members of PHARMACOSMOS HOLDING A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Statsaut. revisor Karl Aage Jensen | Audit | 0 companies |
| Tobias Sidelmann Christensen | Chief Executive Officer | 0 companies |
| Henrik Parker | Management | 0 companies |
| Robert Guglielmetti | Management | 0 companies |
| Tommy Pedersen | Board of Directors | 0 companies |
| Lars Christensen | Chairman | 0 companies |
| Jacob Tolstrup | Chairman | 0 companies |
| Henry Marinus Christensen | Chairman | 0 companies |
| Lars Juul Peitersen | Board of Directors | 0 companies |
| Milena Jordanova Olsen | Board of Directors | 0 companies |
| Annemarie Sidelmann | Chairman | 0 companies |
| Torkil Christensen | Board of Directors | 0 companies |
| Gudrun Haugen Christensen | Board of Directors | 0 companies |
| Axel Kierkegaard | Chairman | 0 companies |